# BDTX-1535-101: what clinicians are saying

> 37 statements from 12 sources (1 podcast, 2 videos, 9 posts), 19 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
- NCT ID: NCT05256290
- Registry: https://clinicaltrials.gov/study/NCT05256290
- Sponsor: Black Diamond Therapeutics, Inc.
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: silevertinib (BDTX-1535)
- Indication: EGFR-mutated NSCLC or glioblastoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: bc5e323ecc8c667372798668ea1e8f5536d8256581c3000b9e04f8cb9beca9b7

## Counts

- Commentary sources screened: 25
- Sources cited by verified statements: 12
- Verified statements: 37
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 19
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 9
- Speakers cited: 9
- Cited speakers with a verified identity: 6
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 6
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 6
- By role and specialty (the abstract's specialty counts):
  - 4 physician, Medical oncology
  - 2 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For BDTX-1535-101, a speaker whose clinical role is unstated questions the proposed starting dose because toxicity required extensive reductions; a medical oncologist relays preserved or deeper responses in most responders following adjustment. The former also questions differentiation from firmonertinib, despite acknowledging a CNS signal. Small numbers and short follow-up qualify the favorable assessment, while cross-study comparisons leave relative benefit uncertain.

## Findings (titles)

- F1. After dose cuts: what speakers say
  - 6 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 1 of the report's 6 cited clinicians.
- F2. Silevertinib's future: where speakers split on non-classical EGFR NSCLC prospects
  - 7 statements from 4 speakers in 6 sources.
  - 4 of the 4 named speakers in this finding take a side on this question.
  - 3 of the report's 6 cited clinicians.
- F3. Non-classical EGFR: what speakers say
  - 10 statements from 6 speakers in 9 sources, 1 of them a podcast or video.
  - 5 of the report's 6 cited clinicians.
- F4. Silevertinib: most speakers note a CNS signal, but one has wider doubts
  - 9 statements from 5 speakers in 6 sources, 2 of them podcasts or videos.
  - 4 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one has wider doubts”.
  - 4 of the report's 6 cited clinicians.
- F5. Mutation targeting, CNS penetration: some speakers see potential but seek validation
  - 17 statements from 4 speakers in 5 sources, 3 of them podcasts or videos.
  - 2 of the 4 named speakers in this finding hold this view; 3 of the 4 hold its caveat, “seek validation”.
  - 1 of the report's 6 cited clinicians.
- F6. Oral use: a clinician values convenience but ties QoL gains to efficacy & tolerability
  - 5 statements from 2 speakers in 3 sources, 2 of them podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “tie QoL gains to efficacy & tolerability”.
  - 1 of the report's 6 cited clinicians.

### Beyond the trial population

- F7. Post-osimertinib: a clinician favors retesting and asks how to tailor care
  - 4 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “ask how to tailor care”.
  - 1 of the report's 6 cited clinicians.

1 of the 7 findings and 3 of the 37 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 6 | 4 | 3 | 2 | 3 |
| F2 | 7 | 6 | 6 | 4 | 3 |
| F3 | 10 | 9 | 9 | 6 | 4 |
| F4 | 9 | 7 | 6 | 5 | 3 |
| F5 | 17 | 12 | 5 | 4 | 4 |
| F6 | 5 | 4 | 3 | 2 | 2 |
| F7 | 4 | 3 | 1 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 0 | 0 | 1 | 1 | 6 | 1 | 2 posts and articles, 1 podcast or video |
| F2 | 5 | 1 | 0 | 1 | 0 | 9 | 0 | 6 posts and articles |
| F3 | 6 | 1 | 1 | 2 | 0 | 12 | 1 | 8 posts and articles, 1 podcast or video |
| F4 | 7 | 0 | 1 | 1 | 0 | 9 | 0 | 4 posts and articles, 2 podcasts and video |
| F5 | 5 | 4 | 2 | 1 | 5 | 18 | 0 | 2 posts and articles, 3 podcasts and video |
| F6 | 2 | 0 | 1 | 2 | 0 | 5 | 0 | 1 post or article, 2 podcasts and video |
| F7 | 3 | 0 | 1 | 0 | 0 | 4 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535): F4 (1 shared claims), F5 (2 shared claims), F6 (1 shared claims)
- Primary endpoint: Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535): F1 (1 shared claims), F2 (3 shared claims), F3 (7 shared claims), F4 (5 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Primary endpoint: Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose: F1 (1 shared claims), F2 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Secondary endpoint: Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM): F4 (1 shared claims), F5 (4 shared claims)
- Secondary endpoint: Phase 2: To assess progression free survival by RECIST version 1.1: F1 (1 shared claims), F2 (2 shared claims), F3 (5 shared claims), F4 (3 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Secondary endpoint: Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535): no finding draws on it directly
- Population and setting: F1 (1 shared claims), F2 (1 shared claims), F3 (5 shared claims), F4 (4 shared claims), F5 (7 shared claims), F6 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (5 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (3 shared claims), F5 (4 shared claims), F6 (5 shared claims)
- Design and conduct: F1 (2 shared claims), F3 (2 shared claims), F4 (2 shared claims), F5 (4 shared claims), F6 (1 shared claims)

## Abbreviations

- CNS: central nervous system
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MTD: maximum tolerated dose
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- RECIST: Response Evaluation Criteria in Solid Tumors
- RP2D: recommended phase 2 dose

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 37 | Paid |
| Who said each statement: the cited speakers | 9 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 6 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 17 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 6 of the 9 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

16 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535) | discussed | 2 | 2 |
| Primary endpoint: Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535) | discussed | 8 | 8 |
| Primary endpoint: Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose | discussed | 1 | 1 |
| Secondary endpoint: Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM) | discussed | 4 | 2 |
| Secondary endpoint: Phase 2: To assess progression free survival by RECIST version 1.1 | discussed | 5 | 7 |
| Secondary endpoint: Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535) | no commentary found | 0 | 0 |
| Population and setting | discussed | 13 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 4 | 3 |
| Safety and tolerability | discussed | 7 | 4 |
| Design and conduct | discussed | 6 | 4 |
| CNS activity as a clinically important but narrowly supported signal | discussed | 8 | 6 |
| GBM rationale and disease-specific uncertainty | discussed | 6 | 3 |
| Mechanistic expectations versus demonstrated clinical differentiation | discussed | 7 | 3 |
| Biomarker work-up and resistance-informed selection | discussed | 5 | 1 |
| Competitive positioning, registration uncertainty and alternative treatment strategies | discussed | 5 | 2 |
| Oral convenience and conditional quality-of-life value | discussed | 1 | 1 |
| Evidence maturity and the questions speakers left open | discussed | 8 | 7 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 23 statements · 62%** | | | |
| YouTube | 10 | 2 | 2 |
| Podcasts | 13 | 1 | 1 |
| **Posts · 14 statements · 38%** | | | |
| X threads | 14 | 9 | 22 |

- Screened window: 2022-04-05 to 2026-10-25
- Cited window: 2022-04-05 to 2026-09-02
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
- Registry: NCT05256290 (https://clinicaltrials.gov/study/NCT05256290)
- Study IDs: BDTX-1535-101
- Sponsor: Black Diamond Therapeutics, Inc.
- Design: Phase 1/Phase 2 · interventional, non randomized, sequential, phase1, phase2
- Status: Recruiting
- Enrollment: 220 (estimated)
- Start: 2022-03-31 (actual)
- Primary completion: 2028-03 (estimated)
- Primary endpoint: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535) (The first treatment 21-day cycle (Cycle 1))
- Primary endpoint: Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535) (Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days))
- Primary endpoint: Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose (Through study completion, approximately 1 year)
- Intervention: silevertinib monotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about how the inhibitor’s design enables selective targeting of oncogenic EGFR mutations; a question about initial research findings for the investigational EGFR inhibitor.
- 16 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 22 sources about other trials or topics are not included.
- The sources reviewed for this edition do not represent all HCP discussion or support estimates of agreement, adoption or sentiment prevalence. Repeated posts and reposts should not be counted as additional independent opinions.
- Discussion that does not name the trial or known aliases, or that uses different transcription variants, may be absent.
- Questions introducing initial research findings and inhibitor design are not represented by available statements; some framing of the interview is therefore missing.
- No exact-trial results publication, full protocol or silevertinib-monotherapy prescribing label was identified in the available material. Reported outcome and development details therefore remain attributed to the interviews, video and X accounts.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The 77% and 84% dose-reduction accounts cannot be reconciled from the statements available. Post-reduction activity does not establish the performance of a prospectively assigned 150 mg starting dose.
- The video renders a mutation subset as TAF, whereas other accounts discuss PACC. The report does not correct or equate those terms.
- Cross-treatment efficacy and safety appraisals are historical or cross-study interpretations, not randomized comparisons. Short follow-up and small molecular and CNS subgroups limit generalization.
- Development aims from 2022, initial experience from 2023 and later congress-related accounts retain their original timing; they should not be combined into an assumed current trial status.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 37 verified statements · 19 from 6 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (6 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/bdtx-1535-101-nct05256290
- Agents: POST https://www.erudio.com/api/orders with {"report": "bdtx-1535-101-nct05256290", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=bdtx-1535-101-nct05256290

## Cite

Erudio Health. BDTX-1535-101 (NCT05256290): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/bdtx-1535-101-nct05256290

## Questions

### How much does the BDTX-1535-101 report cost?

One edition costs $750 (Focused · 37 verified statements · 19 from 6 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the BDTX-1535-101 report cover?

37 statements from 12 sources (1 podcast, 2 videos, 9 posts), 19 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the BDTX-1535-101 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "bdtx-1535-101-nct05256290" }) previews it and create_order({ "report": "bdtx-1535-101-nct05256290", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the BDTX-1535-101 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/bdtx-1535-101-nct05256290.json
- Markdown: https://www.erudio.com/reports/bdtx-1535-101-nct05256290.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/bdtx-1535-101-nct05256290/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "bdtx-1535-101-nct05256290"}`
